MetaVia Inc. (MTVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MetaVia Inc. (MTVA) has a cash flow conversion efficiency ratio of -0.551x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.76 Million) by net assets ($6.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MetaVia Inc. (MTVA) total market value for the company's overall valuation and market capitalisation.
MetaVia Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how MetaVia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
MetaVia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MetaVia Inc. ranked by their cash flow conversion efficiency. See MTVA operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SANCUS LENDING GROUP LTD.
F:97F
|
N/A |
|
Strategic Resources Inc
V:SR
|
-0.008x |
|
Akdeniz Yatirim Holding AS
IS:AKYHO
|
0.058x |
|
Patria Private Equity Trust
LSE:PPET
|
-0.001x |
|
SL Private Equity
LSE:SLPE
|
-0.001x |
|
Boule Diagnostics AB
ST:BOUL
|
-0.017x |
|
Omineca Mining and Metals Ltd
V:OMM
|
-0.046x |
|
Ekiz Kimya Sanayi ve Ticaret AS
IS:EKIZ
|
-0.296x |
Annual Cash Flow Conversion Efficiency for MetaVia Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of MetaVia Inc. from 2014 to 2025. View MetaVia Inc. (MTVA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.33 Million | $-15.70 Million | -2.944x | +5.50% |
| 2024-12-31 | $7.93 Million | $-24.71 Million | -3.116x | -381.38% |
| 2023-12-31 | $16.68 Million | $-10.80 Million | -0.647x | -20.19% |
| 2022-12-31 | $21.75 Million | $-11.71 Million | -0.538x | +48.06% |
| 2021-12-31 | $14.60 Million | $-15.13 Million | -1.037x | +30.62% |
| 2020-12-31 | $7.20 Million | $-10.76 Million | -1.494x | -160.96% |
| 2019-12-31 | $12.29 Million | $-7.04 Million | -0.573x | -152.65% |
| 2018-12-31 | $-13.29 Million | $-14.45 Million | 1.088x | +115.93% |
| 2017-12-31 | $3.94 Million | $-26.90 Million | -6.826x | -1175.31% |
| 2016-12-31 | $20.63 Million | $-11.04 Million | -0.535x | -221.96% |
| 2015-12-31 | $-12.38 Million | $-5.43 Million | 0.439x | +19.50% |
| 2014-12-31 | $-531.00K | $-195.00K | 0.367x | -- |
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as … Read more